Medical Imaging AI Competitions Lack Fairness

arXiv:2512.17581 · cs.CV · Submitted 2025-12-19 · Read on arXiv

Listen

Radio episode about this paper

Transcript

Introduction to the show: ident: AI Radio. Generated commentary on the latest Artificial Intelligence papers.

Tom: We're looking at the paper: "Medical Imaging AI Competitions Lack Fairness".

Jane: Here's the gist of the paper. Benchmarking competitions are central to the development of artificial intelligence (AI) in medical imaging, defining performance standards and shaping methodological progress In this work, we assess fairness along two complementary dimensions: (1) whether challenge datasets capture the diversity of real-world clinical data, and (2) whether they are accessible and legally reusable in line with the FAIR principles Our findings reveal limited representation across challenge datasets with respect to geographic location, imaging modalities, and problem types, raising concerns about how well current benchmarks reflect real-world clinical diversity Despite their widespread influence, challenge datasets were frequently constrained by restrictive or ambiguous access conditions, inconsistent or non-compliant licensing practices, and incomplete documentation Together, these shortcomings expose foundational fairness limitations in our benchmarking ecosystem and highlight a disconnect between leaderboard success and clinical relevance.

Tom: Systematic Study Scope The study conducted a large-scale systematic study of 249 biomedical image analysis challenges comprising 458 tasks across 19 imaging modalities This comprehensive review aimed to assess fairness along two complementary dimensions: (1) whether challenge datasets capture the diversity of real-world clinical data, and (2) whether they are accessible and legally reusable in line with the FAIR principles.

Jane: The analysis included 458 tasks across 19 modalities.

Tom: Limited Data Representativeness The analysis revealed substantial overrepresentation of certain geographic regions and imaging modalities, alongside a strong predominance of specific problem types and anatomical regions Specifically, 70% of tasks used data originated from the United States, followed by China (16%), Germany (13%), the Netherlands (10%), and the United Kingdom (10%).

Title and authors: Tom: So we’re starting by looking at the title of this paper, "Medical Imaging AI Competitions Lack Fairness," and who wrote it. It immediately tells you that the core issue is about fairness within these competition settings.

Jane: And the authors list a pretty big team from places like Germany, The Netherlands, and oncode Institute in the United States, which shows they have a wide perspective on this problem.

Tom: Right, and what they are really pointing out is that even though these competitions drive progress in medical imaging AI development by setting performance standards, the data behind those challenges isn't representative of the actual clinical world.

Jane: That’s the big takeaway there—we think the benchmarks are missing crucial real-world diversity in geography, and they also have serious issues with how easy it is to actually use or reuse that data legally.

Lu: From my side, I’m interested in how this lack of representation affects the model generalization. If a benchmark only sees data from one country or one type of machine, the resulting AI won't perform well when deployed in a different clinic with different equipment.

Meng: I wonder if that means the models we train on these benchmarks are just optimized for academic signaling rather than actually being robust enough for real deployment at scale where data is messy and diverse.

Lalam: My analysis of the literature confirms that this issue of data bias in benchmarking is a recurring theme, and this paper systematically proves it across a huge set of tasks.

The paper's summary: Tom: So let's go into what they actually found. The study looked at four hundred fifty-eight tasks across nineteen modalities, and the results showed that the data in these challenges is heavily skewed geographically and by imaging type <ref:2512.17581#pg2>.

Jane: They found limited representation across geographic location, which is pretty telling because we expect to see more diversity reflecting how healthcare systems operate around the world.

Tom: Specifically, seventy percent of the tasks used data from the United States alone, followed by China at sixteen percent, Germany at thirteen percent, and then The Netherlands and the United Kingdom at ten percent each.

Jane: That means North America and Europe are way overrepresented compared to global population distribution—the study found they were overrepresented by about fifteen point nine percent and seven point nine percent respectively.

Lu: And it’s not just geography; they also saw a strong predominance of specific problem types and anatomical regions, which limits how broadly the AI can actually be applied clinically.

Meng: That makes sense from an engineering standpoint; if we only train on one type of scan, the model will struggle when you get a case from a completely different modality.

Lalam: And on top of that, there are serious problems with accessibility and licensing, which is another dimension they assessed alongside the data diversity.

The paper's improvements: Tom: Moving to the next part, the authors don't just point out the problems; they suggest some concrete improvements for how these challenges should be designed going forward.

Jane: They are pushing for better data capture, suggesting that future datasets need to prioritize geographic diversity and a wider variety of imaging modalities to reflect real clinical variation.

Tom: And on the accessibility front, they want baseline requirements for metadata and licensing—things like machine-readable metadata and clear, standardized licensing information using frameworks like RDP or Croissant.

Lu: That’s a big shift toward making the data ecosystem more transparent and legally certain so that researchers can actually reuse the data without hitting roadblocks.

Meng: From my perspective on deployment, I need that legal clarity. Ambiguous terms or inconsistent licensing practices create huge risks for production systems where we need to know exactly what we are allowed to use and redistribute.

Lalam: They also suggest updating reporting guidelines, like the BIAS reporting guideline, to include fairness considerations and mandating more detailed documentation about things like data splitting strategies and ethics committee approvals.

Conclusion: Tom: So wrapping up the paper "Medical Imaging AI Competitions Lack Fairness," the authors conclude that there is a significant mismatch between leaderboard success in these competitions and what’s actually needed for clinical readiness.

Jane: They argue that benchmarks often prefer problems that are easy to measure and feasible to study rather than those of greatest actual clinical relevance, which means we have to rethink what we optimize for.

Lu: The implication is that current benchmarking practices might be serving academic signaling instead of genuinely supporting AI development in a way that helps diverse patient populations.

Meng: And from a production standpoint, this means we need to move beyond just high performance numbers and start evaluating properties like robustness or workflow integration before we even think about deploying these models.

Lalam: To summarize the core finding is that the datasets are often not representative of real-world clinical use, and they face major hurdles with accessibility and reuse documentation.

Tom: That’s what this paper does by systematically assessing these two dimensions—representation and FAIR principles—and it really highlights a gap between where AI research is going on the leaderboard and where it needs to go clinically.

Jane: So, for anyone listening, the message is that we need more diversity in our data sources and much clearer rules about how we can legally use that data so this technology helps everyone.

cs.CV

Submitted: 2025-12-19

Updated: 2026-11-05

Comments: Minor revision at Nature Biomedical Engineering

License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/

Importance score: 81/100

The gist: Benchmarking competitions are central to the development of artificial intelligence (AI) in medical imaging, defining performance standards and shaping methodological progress In this work…

Key concepts

Data Representativeness
This refers to whether the datasets used in competitions accurately reflect the global diversity of real-world patient data. The study found major biases, with most tasks using data from North America and Europe, while other regions and imaging types were severely underrepresented.
FAIR Principles
FAIR stands for Findable, Accessible, Interoperable, and Reusable. This concept dictates that data should be easy to find and use. The study found many challenge datasets failed this principle due to inconsistent licensing terms and ambiguous access conditions.
Benchmarking Fairness
This involves evaluating whether the standards set by competitions are fair across different contexts. The research concluded that current benchmarks favor problems that are easy to measure rather than those most relevant for diverse clinical settings, creating a disconnect between performance and real-world application.

Terminology

Summary

Benchmarking competitions are central to the development of artificial intelligence (AI) in medical imaging, defining performance standards and shaping methodological progress In this work, we assess fairness along two complementary dimensions: (1) whether challenge datasets capture the diversity of real-world clinical data, and (2) whether they are accessible and legally reusable in line with the FAIR principles Our findings reveal limited representation across challenge datasets with respect to geographic location, imaging modalities, and problem types, raising concerns about how well current benchmarks reflect real-world clinical diversity Despite their widespread influence, challenge datasets were frequently constrained by restrictive or ambiguous access conditions, inconsistent or non-compliant licensing practices, and incomplete documentation Together, these shortcomings expose foundational fairness limitations in our benchmarking ecosystem and highlight a disconnect between leaderboard success and clinical relevance. p. 1

Systematic Study Scope

The study conducted a large-scale systematic study of 249 biomedical image analysis challenges comprising 458 tasks across 19 imaging modalities This comprehensive review aimed to assess fairness along two complementary dimensions: (1) whether challenge datasets capture the diversity of real-world clinical data, and (2) whether they are accessible and legally reusable in line with the FAIR principles. The analysis included 458 tasks across 19 modalities. p. 1

Limited Data Representativeness

The analysis revealed substantial overrepresentation of certain geographic regions and imaging modalities, alongside a strong predominance of specific problem types and anatomical regions Specifically, 70% of tasks used data originated from the United States, followed by China (16%), Germany (13%), the Netherlands (10%), and the United Kingdom (10%). Relative to the global population distribution, North America and Europe were overrepresented by factors of 15. p. 49 and 7.9, whereas Africa (0. p. 41), South America (0. p. 42), and Asia (0. p. 45) were underrepresented relative to the global population. p. 4 Furthermore, MRI was 4. p. 44-fold overrepresented in challenges relative to the reported clinical utilization distribution, whereas ultrasound was severely underrepresented (ratio: 0. p. 42).

Accessibility and Licensing Barriers

The study exposed widespread issues in data accessibility, licensing practices, and documentation quality Among the barriers to reuse, 80% of datasets exhibited some form of inconsistency in data licensing or access practices. The median score across tasks on a 0-5 scale, reflecting the clarity of licensing terms and accessibility, was 3. p. 7 Notably, 46% of tasks received a score of 2. p. 75 or lower, reflecting difficulties in locating definitive licensing information or ambiguous terms that complicated interpretation. p. 7

Documentation and Reporting Gaps

Widespread reporting gaps hinder reusability and reproducibility due to missing documentation across multiple dimensions Key deficiencies in reporting include:

**% of tasks where the challenge website was no longer functional was 3%. **

**% of tasks did not report whether ethics committee approval had been obtained was 35%. p. 2 **

**% of tasks reported sufficient description of the data splitting strategy was 19%. p. 8 **

**% of tasks reported de-identification procedures was 40%. p. 4 **

Implications for Clinical Relevance

The findings suggest that benchmarks may prefer problems that are readily measurable and feasible to study rather than those of greatest clinical relevance This challenges the implicit assumption that leaderboard success equates to clinical readiness. The mismatch between challenge data characteristics and real-world clinical utilization raises fairness concerns by implicitly centering resource-rich healthcare systems, thereby disadvantaging regions where alternative diagnostic tools are primary. p. 1 Ultimately, these problems raise the broader question of whether current benchmarking practices are aligned with real-world application needs or increasingly serve academic signaling rather than supporting clinically meaningful AI development. p. 2

Future Directions for Improvement

Emerging approaches aim to improve transparency, provenance, and legal certainty in dataset design Concrete steps include:

** Introducing baseline requirements for metadata and licensing, such as machine-readable metadata and clear, standardized licensing information through schemas like RDP or Croissant. **

** Updating reporting guidelines, such as the BIAS reporting guideline, to include fairness-related considerations. **

** Complementary infrastructure-oriented work proposes machinereadable, policy-as-code governance layers to increase transparency and auditability. p. 8 **

** Establishing such requirements at the point of submission undergoing peer review would reduce ambiguity and support lawful reuse.

Green — the paper says it, and the page is printed. Red — no passage carries it, so treat that sentence as unverified. The same check runs on your own text: check a summary against its source, $5.

Improvements for AI systems

  1. Data acquisition should prioritize geographic diversity to avoid biases in model generalization, as 70% of tasks used data originated from the United States, followed by China (16%), Germany (13%), the Netherlands (10%), and the United Kingdom (10%) according to Section 3.2. This addresses Fairness in representativeness concerns whether datasets reflect real-world conditions, such as geographic or clinical variation.

  2. Implement automated data governance layers using policy as code to decouple policy definition from enforcement, aiming to increase transparency, auditability, and legal clarity in decentralized AI data ecosystems according to the discussion section. This mitigates risks associated with conflicting license statements across different sources and additional data usage agreements that may contradict open licenses.

  3. Develop standardized metadata requirements for challenge submissions using machine-readable formats like schema.org or the Reusable Data Project framework to ensure clear, machine-readable expressions of licensing terms and reduce ambiguity in reuse conditions. This directly addresses the Critical flaws in data accessibility, licensing, and documentation identified by the authors.

  4. Incorporate comprehensive reporting standards into challenge guidelines that mandate detailed socio-demographic and clinical information, such as study design, data splitting strategy, acquisition devices, and ethics approval status. This counters the Widespread reporting gaps hinder reusability and reproducibility by ensuring that clinical information such as disease status, diagnosis, or treatment history per subjects was absent in 40% of tasks.

  5. Establish a mechanism to evaluate the practical impact of benchmark success versus clinical readiness, moving beyond leaderboard position by assessing properties required for successful clinical deployment such as robustness or workflow integration rather than just performance metrics. This addresses the concern that leaderboard success equates to clinical readiness, suggesting a shift in how algorithms are optimized.

Sources

Related papers